“The new version of Sputnik V against the delta and omicron strains is the most promising variant of the vaccine adapted to new strains of the virus,” says the Gamaleya center.
The Gamaleya Moscow National Research Center for Epidemiology and Microbiology has developed a new version of its Sputnik V coronavirus vaccine adapted against variants delta and omicron.
“The new version of Sputnik V against delta and omicron strains is the most promising variant of the vaccine adapted to new strains of the virus, also in comparison with similar drugs combined against the original strain (Wuhan) and omicron,” the institution said in a statement issued on Tuesday.
The Gamaleya center explains that the drug achieved a “a reliable reduction in viral load” accumulated in the lungs of infected animals and affirms that “it will also allow achieving high results in the disease prevention“.
Meanwhile, this month marks two years since Russia registered Sputnik V, the world’s first coronavirus vaccine.
Today the drug, which was named in honor of the first Soviet satellite, is registered in 71 countries with a total population of over 4 billion people. Likewise, studies on Sputnik V have been published in the main international peer-reviewed medical journals, such as The Lancet, Nature, Vaccines or Cell Reports Medicine, among others.
“Sputnik V has become the most exported drug in the history of Russia and it is one of the vaccines against the coronavirus most effective and safest in the world“, pointed out the Gamaleya center, recalling that the current version of the vaccine “continues to show excellent results in preventing hospitalization and deaths.”